EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Biologic Therapy Carries a Very Low Risk of Reactivation in Hepatitis B Surface Antigen-Negative Phase of Hepatitis B

İlkay Ergenç, Haluk Tarık Kani, Murat Karabacak, Elif Cömert Özer, Shahin Mehdiyev, Fuad Jafarov, Kerem Yiğit Abacar, Seda Kutluğ Ağaçkıran, Gizem Sevik, Rahmi Aslan, Fatma Alibaz Öner, Nevsun İnanç und 6 weitere

Turkish Journal of Gastroenterology · 2022

DOI: 10.5152/tjg.2022.22196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Turkish Journal of Gastroenterology, 2022. Verfasst von İlkay Ergenç und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Marmara University Faculty of Medicine, İstanbul, Turkey. Hauptthemen laut MEDLINE: Biological Products, Hepatitis B, Hepatitis B Surface Antigens, Latent Infection. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The risk of hepatitis B reactivation in hepatitis B surface antigen-negative phase of hepatitis B virus-infected patients exposed to biologic agents is not clear. We aimed to investigate the reactivation rate in hepatitis B surface antigen-negative phase of hepatitis B virus-infected patients after biologic therapy.

Methods

Patients followed at gastroenterology, rheumatology, and dermatology clinics with a diagnosis of immune-mediated inflammatory diseases were screened. Immune-mediated inflammatory diseases patients exposed to biologic agents with a negative hepatitis B surface antigen and positive hepatitis B core immunoglobulin G antibody were included in the study.

Results

We screened 8266 immune-mediated inflammatory disease patients, and 2484 patients were identified as exposed to biologic agents. Two hundred twenty-one patients were included in the study. The mean age was 54.08 ± 11.69 years, and 115 (52.0%) patients were female. The median number of different biologic subtype use was 1 (range: 1-6). The mean biologic agent exposure time was 55 (range: 2-179) months. One hundred and fifty-two (68.8%) patients used a concomitant immunomodulatory agent, and 84 (38.0%) patients were exposed to corticosteroids during biologic use. No hepatitis B reactivation with a reverse seroconversion of hepatitis B surface antigen positivity was seen. Antiviral prophylaxis for hepatitis B was applied to 48 (21.7%) patients. Hepatitis B virus-DNA was screened in 56 (25.3%) patients prior to the biologic exposure. Two patients without antiviral prophylaxis had hepatitis B virus-DNA reactivation with a negative hepatitis B surface antigen during exposure to the biologic agent.

Conclusion

We found 2 reactivations and no hepatitis B surface antigen seroconversion in our cohort. Antiviral prophylaxis for patients exposed to biologic agents may need to be discussed in more detail. Cite this article as: Ergenç İ, Kani HT, Karabacak M, et al. Biologic therapy carries a very low risk of reactivation in hepatitis B surface antigen-negative phase of hepatitis B. Turk J Gastroenterol. 2023;34(2):156-160.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsHepatitis BHepatitis B Surface AntigensLatent InfectionVirus ActivationAdultAgedFemaleHumansMaleMiddle AgedAntigens, SurfaceAntiviral AgentsBiological TherapyHepatitis B AntibodiesHepatitis B virusRetrospective Studies

Substanzen

Antigens, SurfaceAntiviral AgentsBiological ProductsHepatitis B AntibodiesHepatitis B Surface Antigens

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Internal Medicine, Marmara University Faculty of Medicine, İstanbul, Turkey.
  • Division of Rheumatology, Department of Internal Medicine, Marmara University Faculty of Medicine, İstanbul, Turkey.
  • Department of Dermatology, Marmara University Faculty of Medicine, İstanbul, Turkey.

Zitieren

APA

Ergenç, İ., Kani, H. T., Karabacak, M., Cömert Özer, E., Mehdiyev, S., Jafarov, F., Abacar, K. Y., Kutluğ Ağaçkıran, S., Sevik, G., Aslan, R., Alibaz Öner, F., İnanç, N., Atagündüz, M. P., Seçkin, D., Özen Alahdab, Y., Ergun, T., Direskeneli, H., & Atuğ, Ö. (2022). Biologic Therapy Carries a Very Low Risk of Reactivation in Hepatitis B Surface Antigen-Negative Phase of Hepatitis B. Turkish Journal of Gastroenterology. https://doi.org/10.5152/tjg.2022.22196

Vancouver

Ergenç İ, Kani HT, Karabacak M, Cömert Özer E, Mehdiyev S, Jafarov F, et al. Biologic Therapy Carries a Very Low Risk of Reactivation in Hepatitis B Surface Antigen-Negative Phase of Hepatitis B. Turkish Journal of Gastroenterology. 2022. doi:10.5152/tjg.2022.22196

BibTeX
@article{Ergen2022,
  author = {Ergenç, İlkay and Kani, Haluk Tarık and Karabacak, Murat and Cömert Özer, Elif and Mehdiyev, Shahin and Jafarov, Fuad and Abacar, Kerem Yiğit and Kutluğ Ağaçkıran, Seda and Sevik, Gizem and Aslan, Rahmi and Alibaz Öner, Fatma and İnanç, Nevsun and Atagündüz, Mehmet Pamir and Seçkin, Dilek and Özen Alahdab, Yeşim and Ergun, Tülin and Direskeneli, Haner and Atuğ, Özlen},
  title = {Biologic Therapy Carries a Very Low Risk of Reactivation in Hepatitis B Surface Antigen-Negative Phase of Hepatitis B},
  journal = {Turkish Journal of Gastroenterology},
  year = {2022},
  doi = {10.5152/tjg.2022.22196}
}
Kostenlos starten →